Taiwan
· Delayed Price · Currency is TWD BioGend Therapeutics Statistics
Total Valuation
BioGend Therapeutics has a market cap or net worth of TWD 4.55 billion. The enterprise value is 3.91 billion.
| Market Cap | 4.55B |
| Enterprise Value | 3.91B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioGend Therapeutics has 124.26 million shares outstanding. The number of shares has increased by 11.65% in one year.
| Shares Outstanding | 124.26M |
| Shares Change (YoY) | +11.65% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 2.56% |
| Float | 81.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.76 |
| PB Ratio | 5.02 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -32.31 |
| EV / Sales | 29.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -29.21 |
Financial Position
The company has a current ratio of 30.20, with a Debt / Equity ratio of 1.24.
| Current Ratio | 30.20 |
| Quick Ratio | 29.45 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -630.84 |
Financial Efficiency
Return on equity (ROE) is -14.08% and return on invested capital (ROIC) is -9.68%.
| Return on Equity (ROE) | -14.08% |
| Return on Assets (ROA) | -9.13% |
| Return on Capital (ROIC) | -9.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | 1.56 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +4.27% |
| 50-Day Moving Average | 36.41 |
| 200-Day Moving Average | 37.46 |
| Relative Strength Index (RSI) | 49.60 |
| Average Volume (20 Days) | 221,465 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioGend Therapeutics had revenue of TWD 133.45 million and -120.92 million in losses. Loss per share was -0.98.
| Revenue | 133.45M |
| Gross Profit | 108.02M |
| Operating Income | -153.29M |
| Pretax Income | -145.88M |
| Net Income | -120.92M |
| EBITDA | -102.96M |
| EBIT | -153.29M |
| Loss Per Share | -0.98 |
Balance Sheet
The company has 655.68 million in cash and 11.23 million in debt, giving a net cash position of 644.44 million or 5.19 per share.
| Cash & Cash Equivalents | 655.68M |
| Total Debt | 11.23M |
| Net Cash | 644.44M |
| Net Cash Per Share | 5.19 |
| Equity (Book Value) | 908.81M |
| Book Value Per Share | 7.29 |
| Working Capital | 717.54M |
Cash Flow
In the last 12 months, operating cash flow was -125.27 million and capital expenditures -8.45 million, giving a free cash flow of -133.72 million.
| Operating Cash Flow | -125.27M |
| Capital Expenditures | -8.45M |
| Free Cash Flow | -133.72M |
| FCF Per Share | -1.08 |
Margins
Gross margin is 80.95%, with operating and profit margins of -114.87% and -90.61%.
| Gross Margin | 80.95% |
| Operating Margin | -114.87% |
| Pretax Margin | -109.32% |
| Profit Margin | -90.61% |
| EBITDA Margin | -77.15% |
| EBIT Margin | -114.87% |
| FCF Margin | -100.21% |
Dividends & Yields
BioGend Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.65% |
| Shareholder Yield | -11.65% |
| Earnings Yield | -2.68% |
| FCF Yield | -2.94% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |